Literature DB >> 8797589

Molecular determinants in the plasma clearance and tissue distribution of ribonucleases of the ribonuclease A superfamily.

V M Vasandani1, Y N Wu, S M Mikulski, R J Youle, C Sung.   

Abstract

The similarities and differences among members of the RNase A superfamily provide an ideal opportunity to examine the molecular basis for differences in their pharmacokinetics and biodistribution. Plasma clearances in BALB/c mice are similar among the five RNases studied: human pancreatic RNase, angiogenin, eosinophil-derived neurotoxin, onconase, and bovine seminal RNase. The average clearance is 0.13 ml/min or 60% of the glomerular filtration rate (measured by [14C]inulin clearance during continuous infusion from an i.p. implanted osmotic pump). Angiogenin has a higher volume of distribution and plasma-to-muscle transport rate than the other RNases, suggestive of binding to endothelial cells. Organ distribution differs dramatically among these RNases. The RNase most toxic to tumor cells, onconase, exhibits the longest retention in the kidneys: at 180 min, 50% of the injected dose is found in the kidneys, whereas only 1% or less of the other RNases is retained in the kidneys. Slower elimination of onconase from the kidneys may be due to a higher degree of binding in the kidney or a resistance to proteolytic degradation. To elucidate the molecular determinants involved in tissue uptake, we examined the biodistribution of recombinant onconase and two onconasepancreatic RNase chimeric proteins. The tissue retention property of onconase appears to be located in at least two regions, one of which is in the NH2-terminal 9-amino acid alpha-helix. The NH2-terminal pyroglutamate of onconase, a residue essential for ribonucleolytic activity and cytotoxicity, does not play a role in kidney retention.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8797589

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

Review 1.  Cancer chemotherapy--ribonucleases to the rescue.

Authors:  P A Leland; R T Raines
Journal:  Chem Biol       Date:  2001-05

2.  Urinary Angiogenin Reflects the Magnitude of Kidney Injury at the Infrahistologic Level.

Authors:  Quentin Tavernier; Iadh Mami; Marion Rabant; Alexandre Karras; Pierre Laurent-Puig; Eric Chevet; Eric Thervet; Dany Anglicheau; Nicolas Pallet
Journal:  J Am Soc Nephrol       Date:  2016-07-19       Impact factor: 10.121

Review 3.  tRNA fragmentation and protein translation dynamics in the course of kidney injury.

Authors:  Iadh Mami; Nicolas Pallet
Journal:  RNA Biol       Date:  2018-02-12       Impact factor: 4.652

4.  Arginine residues are more effective than lysine residues in eliciting the cellular uptake of onconase.

Authors:  Nadia K Sundlass; Ronald T Raines
Journal:  Biochemistry       Date:  2011-11-04       Impact factor: 3.162

Review 5.  Eosinophils, ribonucleases and host defense: solving the puzzle.

Authors:  H F Rosenberg; J B Domachowske
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

6.  Neomycin inhibits angiogenin-induced angiogenesis.

Authors:  G F Hu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

Review 7.  Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity.

Authors:  Thomas J Rutkoski; Ronald T Raines
Journal:  Curr Pharm Biotechnol       Date:  2008-06       Impact factor: 2.837

8.  Molecular docking and dynamics simulations of A.niger RNase from Aspergillus niger ATCC26550: for potential prevention of human cancer.

Authors:  Gundampati Ravi Kumar; Rajasekhar Chikati; Santhi Latha Pandrangi; Manoj Kandapal; Kirti Sonkar; Neeraj Gupta; Chaitanya Mulakayala; Medicherla V Jagannadham; Chitta Suresh Kumar; Sunita Saxena; Mira Debnath Das
Journal:  J Mol Model       Date:  2012-09-16       Impact factor: 1.810

9.  Adenovirus-mediated hPNPase(old-35) gene transfer as a therapeutic strategy for neuroblastoma.

Authors:  Tom Van Maerken; Devanand Sarkar; Frank Speleman; Paul Dent; William A Weiss; Paul B Fisher
Journal:  J Cell Physiol       Date:  2009-06       Impact factor: 6.384

10.  Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma.

Authors:  Camillo Porta; Chiara Paglino; Luciano Mutti
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.